StocksDeepDive
Snapshot · Russell 3000 · generated 2026-09-19 21:53 UTC

XERS — Xeris Biopharma Holdings, Inc.

UNDERVALUED (MOS +62.0%) · Quality 55/100

Price
8.2
Intrinsic value
21.56
Margin of safety
+62.0%
Implied growth (reverse DCF)
+7.5%
model assumes +20.0%
Value Score
39.2
Quality
55
Psychology
-1.8
Discovery
34.7
price/volume attention only
Moat score
47
erosion: none

Value Score: top 38% of Russell 3000 · Quality: top 46%

Open the interactive Deep Dive for XERS →

Use this data programmatically

This page's numbers are also available as JSON at /api/v1/deep-dive/XERS - see the API docs for the full read-only surface, including an MCP server for AI assistants.

Common questions

Is XERS undervalued?

As of 2026-09-19, XERS trades at 8.2 against a computed intrinsic value of 21.56 (+62.0% margin of safety) - StocksDeepDive's valuation label for this is UNDERVALUED. This is a described calculation from public data, not a recommendation.

What is Xeris Biopharma Holdings, Inc.'s Value Score?

Xeris Biopharma Holdings, Inc.'s Value Score is 39.2 as of 2026-09-19 - it combines value, quality, crowd psychology and market attention into one number.